Paradigm Biocapital Advisors Portfolio

Hedge fund & macroParadigm Biocapital Advisors LP 13F holdings · Q3 2026 vs Q2 2026

Why hedge fund & macro: 28 holdings, 11 effective · top 10 75% · turnover 36% a quarter · earnings yield -5.3% (median 2.9%) · 20 quarters of 13Fs

13F value
$5.0bn−5.8%
vs $5.3bn in Q2 2026
Holdings
29
7 new · 4 sold out
Top 10 weight
77.6%
Largest: RVMD 25.4%
Bought est.
$857m
New positions and adds
Sold est.
$363m
Trims and exits
Quarter
Q3 2026
Filed

A 13F is a filing, not a live portfolio. It lists US-listed long stock positions at quarter-end, and it arrives up to 45 days later. Cash, shorts, bonds, options and foreign listings are not in it. Trade sizes here are estimates from the change in share count, restated for stock splits.

Snapshot refreshed